Skip to main content

Table 3 Incidence of treatment emergent adverse events

From: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

TEAE Category

N = 495

Any TEAE

371 (74.9)

Any treatment-relateda TEAE

223 (45.1)

Any serious TEAE

34 (6.9)

Any treatment-relateda serious TEAE

7 (1.4)

Any TEAE leading to discontinuation

84 (17.0)

Any treatment-relateda TEAE leading to discontinuation

66 (13.3)

Any serious TEAE leading to discontinuation

8 (1.6)

Any TEAE leading to death

1 (0.2)

Treatment-related TEAEs (≥2% patients)

 Dyskinesia

57 (11.5)

 Dry mouth

32 (6.5)

 Dizziness

24 (4.8)

 Nausea

22 (4.4)

 Constipation

20 (4.0)

 Insomnia

12 (2.4)

 Hallucination

11 (2.2)

 Fall

10 (2.0)

TEAEs leading to discontinuation (≥1% patients)

 Nausea

10 (2.0)

 Constipation

7 (1.4)

 Hallucination

6 (1.2)

 Dizziness

5 (1.0)

 Dyskinesia

5 (1.0)

  1. aTreatment-related TEAEs were any TEAEs that were considered at least possibly related by the investigator and include the events with missing relationship assessment